Lonza lowered its sales target and core Ebitda margin for 2023, as current market dynamics are hurting demand for early-stage services and nutraceutical capsules.
Lonza lowered its sales target and core Ebitda margin for 2023, as current market dynamics are hurting demand for early-stage services and nutraceutical capsules.